Innate Pharma (IPHA) Payables (2017 - 2025)
Innate Pharma (IPHA) has disclosed Payables for 8 consecutive years, with $17.1 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Payables fell 6.58% year-over-year to $17.1 million, compared with a TTM value of $17.1 million through Dec 2024, down 6.58%, and an annual FY2024 reading of $17.3 million, down 5.89% over the prior year.
- Payables was $17.1 million for Q4 2024 at Innate Pharma, down from $18.3 million in the prior quarter.
- Across five years, Payables topped out at $35.2 million in Q4 2020 and bottomed at $17.1 million in Q4 2024.
- Average Payables over 5 years is $24.9 million, with a median of $21.3 million recorded in 2022.
- The sharpest move saw Payables tumbled 35.73% in 2020, then dropped 6.58% in 2024.
- Year by year, Payables stood at $35.2 million in 2020, then dropped by 7.19% to $32.7 million in 2021, then tumbled by 34.73% to $21.3 million in 2022, then fell by 14.17% to $18.3 million in 2023, then decreased by 6.58% to $17.1 million in 2024.
- Business Quant data shows Payables for IPHA at $17.1 million in Q4 2024, $18.3 million in Q4 2023, and $21.3 million in Q4 2022.